• Katie A Edwards, Joshua J Havelin, Mary I Mcintosh, Haley A Ciccone, Kathlene Pangilinan, Ian Imbert, Tally M Largent-Milnes, Tamara King, Todd W Vanderah, and John M Streicher.
• Department of Biomedical Sciences, College of Osteopathic Medicine, University of New England, Biddeford, Maine.
• J Pain. 2018 Jun 1; 19 (6): 612-625.

AbstractBreast cancer metastasizes to bone, diminishing quality of life of patients because of pain, fracture, and limited mobility. Cancer-induced bone pain (CIBP) is characterized as moderate to severe ongoing pain, primarily managed by mu opioid agonists such as fentanyl. However, opioids are limited by escalating doses and serious side effects. One alternative may be kappa opioid receptor (KOR) agonists. There are few studies examining KOR efficacy on CIBP, whereas KOR agonists are efficacious in peripheral and inflammatory pain. We thus examined the effects of the KOR agonist U50,488 given twice daily across 7 days to block CIBP, tumor-induced bone loss, and tumor burden. U50,488 dose-dependently blocked tumor-induced spontaneous flinching and impaired limb use, without changing tactile hypersensitivity, and was fully reversed by the KOR antagonist nor-binaltorphimine. U50,488 treatment was higher in efficacy and duration of action at later time points. U50,488 blocked this pain without altering tumor-induced bone loss or tumor growth. Follow-up studies in human cancer cell lines confirmed that KOR agonists do not affect cancer cell proliferation. These studies suggest that KOR agonists could be a new target for cancer pain management that does not induce cancer cell proliferation or alter bone loss.Copyright © 2018 The American Pain Society. Published by Elsevier Inc. All rights reserved.

22 keywords...

hide…